NCT01847235View on ClinicalTrials.gov

Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

March 31, 2016

Conditions
Anaplastic OligodendrogliomaAnaplastic Oligoastrocytoma
Interventions
DRUG

Temozolomide

Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT01847235 - Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | Biotech Hunter | Biotech Hunter